This study is in progress, not accepting new patients
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
Summary
- Eligibility
- for people ages 1-25 (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Michelle Hermiston
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCSF
- Michelle Hermiston
Professor Emeritus, Pediatrics, School of Medicine. Authored (or co-authored) 155 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Novartis Pharmaceuticals
- ID
- NCT03876769
- Phase
- Phase 2 research study
- Study Type
- Interventional
- Participants
- About 121 people participating
- Last Updated